IGHE and asthma: All dosage regimens showed a significant decrease in type 2 biomarkers (eosinophil count, FeNO and serum IgE) and annual asthma exacerbation rates, with the most robust effects being observed with the 210 mg/4 weeks regimen, demonstrating significant anti-inflammatory effects and improvement in lung function compared with placebo (Corren et al., 2017).